NCT01968395

Pharmacokinetics of Caspofungin After One Dose in Patients With Liver Failure

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Erasme University Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The objective of this study is to conduct a population pharmacokinetic analysis of caspofungin in a population of patients with moderate and severe acute alcoholic hepatitis or liver disease with Child-Pugh score B and C in order to better characterize pharmacokinetic parameters in case of moderate and severe liver dysfunction.

Detailed description

patients admitted for alcoholic hepatitis or decompensated cirrhosis and Child-Pugh score 7-9 and 10-15 will be included; all patients without invasive aspergillosis.

Conditions

• Bacterial Infections and Mycoses
• Liver Disease

Interventions

Type	Name	Description
DRUG	Caspofungin 70 mg	Intravenous use

Timeline

• Start date: 2013-09-01
• Primary completion: 2014-08-01
• Completion: 2014-10-21
• First posted: 2013-10-24
• Last updated: 2019-02-15

Locations

1 site across 1 country: Belgium